These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 33718019)

  • 1. Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations.
    Yang S; Wang Y; Zhao C; Li X; Liu Q; Mao S; Liu Y; Yu X; Wang W; Tian Q; Pan Y; Xiong A; Chen B; Gao G; Li W; He Y; Wu F; Chen X; Su C; Ren S; Zhou C
    Transl Lung Cancer Res; 2021 Feb; 10(2):753-765. PubMed ID: 33718019
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Specific
    Yang G; Xu H; Hu J; Liu R; Hu P; Yang Y; Li W; Hao X; Zhang S; Xu F; Ai X; Li J; Wang Y
    Front Pharmacol; 2022; 13():806737. PubMed ID: 35330827
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China.
    Xu F; Yang G; Xu H; Yang L; Qiu W; Wang Y
    Thorac Cancer; 2020 Mar; 11(3):679-685. PubMed ID: 31975535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
    Wang Y; Zhang S; Wu F; Zhao J; Li X; Zhao C; Ren S; Zhou C
    BMC Cancer; 2018 Mar; 18(1):326. PubMed ID: 29587667
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical outcomes of patients with
    Zhou J; Ding N; Xu X; Zhang Y; Ye M; Li C; Hu J
    Ther Adv Med Oncol; 2020; 12():1758835920936090. PubMed ID: 32647540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-angiogenic therapy or immunotherapy? A real-world study of patients with advanced non-small cell lung cancer with EGFR/HER2 exon 20 insertion mutations.
    Li J; Xie M; Zhao R; Qiang H; Chang Q; Qian J; Lu H; Shen Y; Han Y; Su C; Chu T
    Front Oncol; 2024; 14():1357231. PubMed ID: 38567147
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for non-small cell lung cancer with EGFR or HER2 exon 20 insertion mutations: a real-world analysis.
    Zhang M; Huang Q; Yu M; Xue J; Huang M; Lu Y; Zhang Y
    Transl Lung Cancer Res; 2023 Apr; 12(4):797-807. PubMed ID: 37197626
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics and prognostic factors of patients with non-small cell lung cancer having HER2 alterations.
    Zhuo X; Guo H; Ma J; Lai J; Liu L; Yin K; Zhao J; Wang J; Jiang F; Xu W; Yuan X; Lin X; Fu G
    J Cancer Res Clin Oncol; 2023 May; 149(5):2029-2039. PubMed ID: 35829744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Association between the HER2 Gene Status and the Efficacy of First-line Pemetrexed Combined with Platinum Chemotherapy in Patients with Advanced Lung 
    Li P; Li B; Shi Y; Zhang F; Shen S; Li X
    Zhongguo Fei Ai Za Zhi; 2019 Mar; 22(3):137-142. PubMed ID: 30909992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR exon 20 insertion mutations in Chinese advanced non-small cell lung cancer patients: Molecular heterogeneity and treatment outcome from nationwide real-world study.
    Yang G; Li J; Xu H; Yang Y; Yang L; Xu F; Xia B; Zhu VW; Nagasaka M; Yang Y; Li Y; Qiu W; Ying J; Ou SI; Wang Y
    Lung Cancer; 2020 Jul; 145():186-194. PubMed ID: 32336530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer.
    Shen X; Chen B; Ma Z; Xie B; Cao X; Yang T; Zhao Y; Qin J; Li J; Cao F; Chen X
    J Recept Signal Transduct Res; 2016; 36(1):89-97. PubMed ID: 26391018
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First-line treatment of advanced epidermal growth factor receptor (EGFR) mutation positive non-squamous non-small cell lung cancer.
    Greenhalgh J; Boland A; Bates V; Vecchio F; Dundar Y; Chaplin M; Green JA
    Cochrane Database Syst Rev; 2021 Mar; 3(3):CD010383. PubMed ID: 33734432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of Second-line Tyrosine Kinase Inhibitors in the Treatment of Metastatic Advanced Non-small-cell Lung Cancer Harboring Exon 19 and 21 EGFR Mutations.
    Zheng Z; Jin X; Lin B; Su H; Chen H; Fei S; Zhao L; Deng X; Xie D; Xie C
    J Cancer; 2017; 8(4):597-605. PubMed ID: 28367239
    [No Abstract]   [Full Text] [Related]  

  • 14. The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
    Wang BC; Zhang WX; Kuang BH; Lin GH
    PLoS One; 2022; 17(10):e0275919. PubMed ID: 36215289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitor Response to HER2 G776(YVMA) In-frame Insertion in HER2-positive Breast Cancer.
    Zheng YB; Yu Y; Chen B; Hu JL; Jing T; Zhang XP
    Cancer Invest; 2016; 34(3):123-9. PubMed ID: 26934461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Resistance of Afatinib in Chinese Non-Small Cell Lung Cancer Patients With
    Song Z; Lv D; Chen S; Huang J; Wang L; Xu S; Chen H; Wang G; Lin Q
    Front Oncol; 2021; 11():657283. PubMed ID: 34026634
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of afatinib in a pretreated patient with invasive mucinous adenocarcinoma of the lung harboring
    He Y; Huang H; Xu M; Fu Z; Zhang X; Chen X; Guo W
    Transl Cancer Res; 2022 Jun; 11(6):1819-1823. PubMed ID: 35836522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Trastuzumab emtansine for patients with non-small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations.
    Iwama E; Zenke Y; Sugawara S; Daga H; Morise M; Yanagitani N; Sakamoto T; Murakami H; Kishimoto J; Matsumoto S; Nakanishi Y; Goto K; Okamoto I
    Eur J Cancer; 2022 Feb; 162():99-106. PubMed ID: 34959152
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pemetrexed-based chemotherapy for non-small-cell lung cancer patients with
    Xu CW; Wang WX; Wang D; Wang QM; Pu XX; Zhu YC; Huang JH; Yu ZY; Cui ZL; Chen XH; Li JL; Fang Y; Wang H; Zhuang W; Lan SJ; Cai X; Zhang YB; Gao WB; Wang LP; She KL; Rao CZ; Zhou YF; Fang MY; Miao LY; Lei L; Lv TF; Song Y
    Transl Lung Cancer Res; 2020 Oct; 9(5):1853-1861. PubMed ID: 33209607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
    Mazières J; Barlesi F; Filleron T; Besse B; Monnet I; Beau-Faller M; Peters S; Dansin E; Früh M; Pless M; Rosell R; Wislez M; Fournel P; Westeel V; Cappuzzo F; Cortot A; Moro-Sibilot D; Milia J; Gautschi O
    Ann Oncol; 2016 Feb; 27(2):281-6. PubMed ID: 26598547
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.